메뉴 건너뛰기




Volumn 96, Issue 11, 2007, Pages 1778-1779

Octreotide and hepatocellular carcinoma

Author keywords

[No Author keywords available]

Indexed keywords

BIM 23A779; HORMONE RECEPTOR BLOCKING AGENT; OCTREOTIDE; PASIREOTIDE; PENTETREOTIDE; SOMATOSTATIN RECEPTOR; SORAFENIB; UNCLASSIFIED DRUG;

EID: 34249829612     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603799     Document Type: Letter
Times cited : (5)

References (9)
  • 1
    • 33846449069 scopus 로고    scopus 로고
    • Becker G, Allgaier HP, Olschewski M, Olschewski M, Zahringer A, Blum HE, HECTOR Study Group et al (2007) Hector Study Group Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 45(1): 9-15
    • Becker G, Allgaier HP, Olschewski M, Olschewski M, Zahringer A, Blum HE, HECTOR Study Group et al (2007) Hector Study Group Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 45(1): 9-15
  • 3
    • 28844480321 scopus 로고    scopus 로고
    • Management of hepatocellular carcinoma
    • Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5): 1208-1236
    • (2005) Hepatology , vol.42 , Issue.5 , pp. 1208-1236
    • Bruix, J.1    Sherman, M.2
  • 4
    • 33749357994 scopus 로고    scopus 로고
    • Cebon J, Australasian Gastro-intestinal Trials group (AGITG) and Ag0001H Investigators (2006) Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 95(7): 853-861
    • Cebon J, Australasian Gastro-intestinal Trials group (AGITG) and Ag0001H Investigators (2006) Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 95(7): 853-861
  • 5
  • 8
    • 33748351565 scopus 로고    scopus 로고
    • Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma
    • Treiber G, Wex T, Rocken C, Fostitsch P, Malfertheiner P (2006) Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 132(11): 699-708
    • (2006) J Cancer Res Clin Oncol , vol.132 , Issue.11 , pp. 699-708
    • Treiber, G.1    Wex, T.2    Rocken, C.3    Fostitsch, P.4    Malfertheiner, P.5
  • 9
    • 0036725135 scopus 로고    scopus 로고
    • A randomized placebo-controlled study of long-acting octreotide for treatment of advanced hepatocellular carcinoma
    • Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BC (2002) A randomized placebo-controlled study of long-acting octreotide for treatment of advanced hepatocellular carcinoma. Hepatology 36(3): 687-691
    • (2002) Hepatology , vol.36 , Issue.3 , pp. 687-691
    • Yuen, M.F.1    Poon, R.T.2    Lai, C.L.3    Fan, S.T.4    Lo, C.M.5    Wong, K.W.6    Wong, W.M.7    Wong, B.C.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.